Integrating Genetic Scores and Plasma proteomics to Understand Type 2 Diabetes Subtypes

Integrating Genetic Scores and Plasma proteomics to Understand Type 2 Diabetes Subtypes

Wednesday, October 9, 2024 12:05 PM to 12:25 PM · 20 min. (Europe/Brussels)
Population Genomics
Presentation
Theatre 11

Information

Find out how combining genetic scores with proteomic data from the UK Biobank can deepen our understanding of type 2 diabetes (T2D) subtypes. Adem will present an analysis identifying 1,860 proteins significantly associated with at least one T2D subtype, with 691 proteins showing exclusive associations. These findings open doors for subtype-specific biomarkers and targeted therapies, advancing precision in T2D treatment.

Olink ProteomicsBooth 610Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, focusing strongly on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to developing our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways. www.olink.com

Registered attendees

Henrik Tommerup
Henrik Tommerup
Strategic Account DirectorOLINK Proteomics
Joseph Pearson
Joseph Pearson
Director, Global Product Management OmicSoft, QDIQIAGEN GmbH
Karl Quinn
Karl Quinn
Director of Data (EMEA)Lifebit

Log in